[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hemiplegia-following-ischemic-stroke\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hemiplegia-following-ischemic-stroke":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,94],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100627374","diaphragm-morphology-and-respiratory-muscle-strength-in-subacute-hemiplegic-patients-100627374",false,"NCT07447804","Diaphragm Morphology and Respiratory Muscle Strength in Subacute Hemiplegic Patients","The Relationship Between Diaphragm Morphology and Respiratory Muscle Strength in Subacute Hemiplegic Patients: A Cross-Sectional Study","Inclusion Criteria:\n\n* Adults aged 18-80 years\n* Clinical diagnosis of hemiplegia\n* Subacute phase (1-6 months post-onset)\n* Ability to tolerate diaphragm ultrasonography and MIP\u002FMEP measurements\n* MMSE score ≥ 24\n* Adequate level of consciousness and ability to cooperate\n\nExclusion Criteria:\n\n* Respiratory comorbidities such as COPD, asthma, or interstitial lung disease\n* Diaphragmatic paralysis or severe chest wall deformity\n* Acute cardiopulmonary conditions preventing respiratory function testing\n* Severe cognitive impairment that may affect measurements\n* Inability to perform ultrasound assessment due to prior gastric or abdominal surgery","ALL","18 Years","80 Years",{"count":20,"type":21},38,"ESTIMATED","1 Day","OBSERVATIONAL","The aim of this study is to determine the relationship between diaphragm morphology (diaphragm excursion, end-inspiratory and end-expiratory diaphragm thickness, and thickening fraction) and respiratory muscle strength (maximum inspiratory pressure - MIP and maximum expiratory pressure - MEP) in patients with subacute hemiplegia.",[26,27,28],"Stroke","Hemiplegia Following Ischemic Stroke","Diaphragm Ultrasonography",[30,31,32,33,34,35,36,37],"Ischemic Stroke","Diaphragm","Ultrasonography","Pulmonary Funtion","Subacute Hemiplegia","Diaphragm morphology","Respiratory muscle strength","Rehabilitation","RECRUITING","2026-03-03",{"date":41,"type":42},"2026-03-05","ACTUAL",{"date":44,"type":42},"2026-02-26",{"date":46,"type":21},"2026-09-26",{"name":48,"class":49},"Fenerbahce University","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":74,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":50},"100597086","phase-1-psychedelic-healing-adjunct-therapy-harnessing-opened-malleability-100597086","NCT07053917","Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability","PHATHOM","Inclusion Criteria:\n\n* Over age 18 years, inclusive.\n* Ischemic or hemorrhagic stroke confirmed by CT or MRI, at least 12 months prior to admission date\n* Ability to give informed consent and understand the tasks involved.\n* Agree that, for the study duration, will refrain from: (1) No new prescription medications during the time of the study without approval of the study team, (2) taking any herbal supplement (except with prior approval of the research team), (3) taking any nonprescription medications with the exception of: 1. non-steroidal anti-inflammatory drugs. 2. acetaminophen. 3. vitamins. 4. or other over-the-counter medications approved by the research team\n* Are willing to follow restrictions and guidelines concerning medications, consumption of food, beverages, and nicotine the night before and just prior to psilocybin administration.\n* Agree to have transportation other than driving themselves home or to where the participants are staying after the administration of psilocybin.\n* Are willing to be contacted via telephone for all necessary telephone contacts.\n* Must have a negative pregnancy test if able to bear children.\n* Must provide a contact (relative, spouse, close friend or other caregiver) who is willing and able to be reached by the investigators in the event of a participant becoming suicidal.\n* Must agree to inform the investigators within 48 hours of any new medical conditions and procedures.\n* Are proficient in speaking and reading English.\n* Agree to have all clinical visit sessions recorded to audio and video.\n* Agree to not participate in any other interventional clinical trials during the duration of this study.\n\nExclusion Criteria:\n\n* Taking one of the following medications in the 30 days prior to psilocybin administration:\n\n  1. selective serotonin reuptake inhibitor (SSRI)\n  2. Serotonin-norepinephrine reuptake inhibitors (SNRI)\n  3. Buproprion\n  4. Valproic acid\n  5. Zolpidem\n  6. Trazodone\n  7. Carbamazepine.\n  8. tricyclic antidepressants\n  9. Monoamine Oxidase Inhibitors\n  10. Mirtazapine\n\n  l. Lithium m. Buspirone n. Atypical antipsychotics o. Zolpidem p.Carbamazepine q. Clonazepam r. Gabapentin s. Lamotrigine t. Levetiracetam u. Phenobarbital v. Phenytoin w. Topiramate x. Valproic Acid y. Zonisamide\n* History of medically significant suicide attempt.\n* Evidence of acute cardiac dysfunction as evidenced by either elevated troponin or EKG changes within 48 hours of administration.\n* Systolic blood pressure that is greater than 150 mmHg systolic on \\> 2 readings during the 7-day monitoring period AND blood pressure medication management has been assured.\n* Diastolic blood pressure that is greater than 100 mmHg systolic on \\> 2 readings during the 7-day monitoring period AND blood pressure medication management has been assured.\n* Systolic blood pressure is less than 90 mmHg systolic on \\> 2 readings during the 7-day monitoring period after blood pressure medication management has been assured.\n* Diastolic blood pressure is less than 30 mmHg systolic on \\> 2 readings during the 7-day monitoring period after blood pressure medication management has been assured.\n* Systolic blood pressure exceeds 160 mmHg or is less than 90 mmHg immediately prior to administration of psilocybin; patients are allowed to be on anti-hypertensives.\n* Diastolic blood pressure exceeds 100 mmHg or is less than 30 mmHg immediately prior to administration of psilocybin; patients are allowed to be on anti-hypertensives.\n* Cognitive impairment that, in the estimation of the study team, would preclude the use of the MindPod Dolphin.\n* History of physical or neurological condition that interferes with study procedures or assessment of motor function (e.g. severe arthritis, severe neuropathy, Parkinson's disease).\n* Social and\u002For personal circumstances that interfere with ability to perform follow up assessments.\n* Are pregnant or nursing.\n* Weigh less than 48 kg.\n* Are not able to give adequate informed consent.\n* Are actively abusing opioids, cocaine, Phencyclidine (PCP), amphetamines, or alcohol.\n* Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (SCID-5) criteria for moderate or severe substance use disorder\n* Diagnosis of schizophrenia, history of prior psychosis, anxiety requiring hospitalization, or Type 1 bipolar.\n* Hypernatremia\n* Hypokalemia (but can have received repletion during the prior 24 hours)\n* Hyperkalemia\n* Glomerular filtration rate of \\\u003C 30 ml\u002Fmin\n* Elevated of white blood cell count\n* Hemoglobin \\\u003C 7 g\u002Fdl\n* Platelet count \\\u003C 100,000 g\u002Fdl\n* Acute cardiac dysfunction demonstrated by either troponin elevation (chronic elevation is acceptable), or EKG changes suggestive of acute coronary syndrome.\n* Active suicidal ideation as assess by the C-SSRS.",{"count":59,"type":21},20,"INTERVENTIONAL",[62],"PHASE1","The main purpose of the current studies is to evaluate the safety and tolerability of psilocybin in patients with chronic stroke.",[26,65,66,67,68,30,69,70,27,71,72,73],"Chronic Stroke","Intracerebral Haemorrhage","Intracerebral Haemorrhage (ICH)","Intracerebral Hemorrhage Basal Ganglia","Ischemic Stroke and Hemorrhagic Stroke","Hemiparesis After Stroke","Hemiplegia and Hemiparesis","Hemiplegia and\u002For Hemiparesis Following Stroke","Middle Cerebral Artery Stroke",[75,76,77,78,79,80,81,82,83,84],"psychedelic","stroke","chronic stroke","intracerebral hemorrhage","stroke recovery","motor recovery","poststroke recovery","poststroke motor recovery","hemiparesis recovery","psychedelic safety","2026-02-11",{"date":87,"type":42},"2026-02-13",{"date":89,"type":42},"2026-02-09",{"date":91,"type":21},"2027-03",{"name":93,"class":49},"Johns Hopkins University",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":60,"phases":104,"briefSummary":106,"conditions":107,"keywords":112,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":4},"100623939","improving-step-in-stroke-patients-100623939","NCT07403149","Improving STEP in Stroke Patients","Evaluating the Improvement of Stepping Quality by Using Adapted Shoes","I-STEP","Inclusion Criteria:\n\n1. Aged over 18 years\n2. With health insurance card \" carte vitale \" (being affiliated to the French security system) on \"ALD\" (Affection de longue durée) meaning reimbursement at a 100% rate\n3. With a past history of stroke (ischemic or hemorrhagic) with a Rankin score 2 to 4, once stabilized (no more improvement), at least 6 months after stroke onset\n4. Spasticity on one side of the body, with spastic walking, with tip-toeing gait, resulting in a \"mowing wheats-like\" movement of the leg as described in the French literature\n5. Patient had full medical examination prior to this research\n6. Informed and written consent of the participant.\n\nExclusion Criteria:\n\n1. Impossible to walk (wheel chair or bedridden)\n2. Diabetic foot\n3. Unhealed and\u002For painful foot injury\n4. Acquired deformity of a foot (osteophytosis, parrot beak on metatarso-phalangeal joint of the first ray, a bunion or hallux valgus, or hallux rigidus or stiffness of the big toe)\n5. Intercurrent disease that may interfere with the evaluation of the primary outcome (Parkinson's disease, peripheral neuropathy, Little's disease, significant hip or knee injury)",{"count":103,"type":21},58,[105],"NA","Stroke is the leading cause of acquired disability in adults. Stroke causes death in 10% of patients, disability and functional handicap in 60% of cases. Sequelea of hemiplegia include spasticity resulting in great difficulty and slowness in walking, gait instability, increasing the risk of falls.\n\nDeambulation may need help (cane, crutch, tripod cane, walker). Lower limb spasticity includes hypertonia of extensors (gluteus maximus, quadriceps, posterior gastrocnemius) resulting in equinovarus. A neurology deficit may be present on ipsilateral lower limb flexors. Hence the patient walks with rubbing of the tip of the foot (tip-toeing gait), resulting in a \"mowing wheatslike\" movement of the leg as described in the French literature. Walking is then slowed down, unstable, with increased risk of falls.\n\nIn post stroke, during the period of rehabilitation and beyond, it is advisable to wear sports shoes although custom-made shoes improve walking and are reimbursed by the French social security system after prior agreement. Most of patients only wear conventional shoes.",[26,27,108,109,110,111],"Disability Physical","Spasticity as Sequela of Stroke","Gluteus Maximus Muscle Atrophy","Equinovarus Foot",[26,113,114,115,116,117],"Hemiplegia","equinovarus","orthopedic shoes","REMARCHE® shoes","Walking performance","NOT_YET_RECRUITING","2026-02-04",{"date":85,"type":42},{"date":122,"type":21},"2026-03-01",{"date":124,"type":21},"2026-04-01",{"name":126,"class":49},"Assistance Publique - Hôpitaux de Paris"]